Cited 0 times in
Fimasartan-Based Blood Pressure Control after Acute Cerebral Ischemia: The Fimasartan-Based Blood Pressure Control after Acute Cerebral Ischemia Study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 남효석 | - |
dc.contributor.author | 이경열 | - |
dc.date.accessioned | 2021-09-29T02:25:18Z | - |
dc.date.available | 2021-09-29T02:25:18Z | - |
dc.date.issued | 2021-07 | - |
dc.identifier.issn | 1738-6586 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/184881 | - |
dc.description.abstract | Background and purpose: Blood pressure (BP) control is strongly recommended, but BP control rate has not been well studied in patients with stroke. We evaluated the BP control rate with fimasartan-based antihypertensive therapy initiated in patients with recent cerebral ischemia. Methods: This multicenter, prospective, single-arm trial involved 27 centers in South Korea. Key inclusion criteria were recent cerebral ischemia within 90 days and high BP [systolic blood pressure (SBP) >140 mm Hg or diastolic blood pressure (DBP) >90 mm Hg]. BP lowering was initiated with fimasartan. BP management during the follow-up was at the discretion of the responsible investigators. The primary endpoint was the target BP goal achievement rate (<140/90 mm Hg) at 24 weeks. Key secondary endpoints included achieved BP and BP changes at each visit, and clinical events (ClinicalTrials.gov Identifier: NCT03231293). Results: Of 1,035 patients enrolled, 1,026 were included in the safety analysis, and 951 in the efficacy analysis. Their mean age was 64.1 years, 33% were female, the median time interval from onset to enrollment was 10 days, and the baseline SBP and DBP were 162.3±16.0 and 92.2±12.4 mm Hg (mean±SD). During the study period, 55.5% of patients were maintained on fimasartan monotherapy, and 44.5% received antihypertensive therapies other than fimasartan monotherapy at at least one visit. The target BP goal achievement rate at 24-week was 67.3% (48.6% at 4-week and 61.4% at 12-week). The mean BP was 139.0/81.8±18.3/11.7, 133.8/79.2±16.4/11.0, and 132.8/78.5±15.6/10.9 mm Hg at 4-, 12-, and 24-week. The treatment-emergent adverse event rate was 5.4%, including one serious adverse event. Conclusions: Fimasartan-based BP lowering achieved the target BP in two-thirds of patients at 24 weeks, and was generally well tolerated. | - |
dc.description.statementOfResponsibility | open | - |
dc.format | application/pdf | - |
dc.language | English | - |
dc.publisher | Korean Neurological Association | - |
dc.relation.isPartOf | JOURNAL OF CLINICAL NEUROLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | Fimasartan-Based Blood Pressure Control after Acute Cerebral Ischemia: The Fimasartan-Based Blood Pressure Control after Acute Cerebral Ischemia Study | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Neurology (신경과학교실) | - |
dc.contributor.googleauthor | Keun Sik Hong | - |
dc.contributor.googleauthor | Sun Uck Kwon | - |
dc.contributor.googleauthor | Jong Ho Park | - |
dc.contributor.googleauthor | Jae Kwan Cha | - |
dc.contributor.googleauthor | Jin Man Jung | - |
dc.contributor.googleauthor | Yong Jae Kim | - |
dc.contributor.googleauthor | Kyung Bok Lee | - |
dc.contributor.googleauthor | Sung Il Sohn | - |
dc.contributor.googleauthor | Yong Seok Lee | - |
dc.contributor.googleauthor | Joung Ho Rha | - |
dc.contributor.googleauthor | Jee Hyun Kwon | - |
dc.contributor.googleauthor | Sang Won Han | - |
dc.contributor.googleauthor | Bum Joon Kim | - |
dc.contributor.googleauthor | Jaseong Koo | - |
dc.contributor.googleauthor | Jay Chol Choi | - |
dc.contributor.googleauthor | Sang Min Sung | - |
dc.contributor.googleauthor | Soo Joo Lee | - |
dc.contributor.googleauthor | Man Seok Park | - |
dc.contributor.googleauthor | Seong Hwan Ahn | - |
dc.contributor.googleauthor | Oh Young Bang | - |
dc.contributor.googleauthor | Yang Ha Hwang | - |
dc.contributor.googleauthor | Hyo Suk Nam | - |
dc.contributor.googleauthor | Jong Moo Park | - |
dc.contributor.googleauthor | Hee Joon Bae | - |
dc.contributor.googleauthor | Eung Gyu Kim | - |
dc.contributor.googleauthor | Kyung Yul Lee | - |
dc.contributor.googleauthor | Mi Sun Oh | - |
dc.identifier.doi | 10.3988/jcn.2021.17.3.344 | - |
dc.contributor.localId | A01273 | - |
dc.contributor.localId | A02648 | - |
dc.relation.journalcode | J01327 | - |
dc.identifier.eissn | 2005-5013 | - |
dc.identifier.pmid | 34184441 | - |
dc.subject.keyword | blood pressure | - |
dc.subject.keyword | fimasartan | - |
dc.subject.keyword | prevention and control | - |
dc.subject.keyword | stroke | - |
dc.contributor.alternativeName | Nam, Hyo Suk | - |
dc.contributor.affiliatedAuthor | 남효석 | - |
dc.contributor.affiliatedAuthor | 이경열 | - |
dc.citation.volume | 17 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 344 | - |
dc.citation.endPage | 353 | - |
dc.identifier.bibliographicCitation | JOURNAL OF CLINICAL NEUROLOGY, Vol.17(3) : 344-353, 2021-07 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.